November 4, 2024
October 7, 2024
Septemebr 23, 2024
Septemebr 9, 2024
August 26, 2024
August 19, 2024
August 5, 2024
July 9, 2024
July 1, 2024
June 11, 2024
May 6, 2024
March 12, 2024
March 5, 2024
February 1, 2024
December 19, 2023
October 12, 2023
October 04, 2023
September 18, 2023
August 15, 2023
June 17, 2023
May 23, 2023
May 3, 2023
April 1, 2023
September 1, 2022
November 29-December 2,2022
July 31-August 4, 2022
San Jose, CA, May 23, 2023
SAN JOSE, CALIFORNIA / ACCESSWIRE / May 23, 2023 / Earlier today Biomed Industries, Inc. issued a letter to the Board of Directors of Neoleukin Therapeutics, Inc. (NASDAQ: NLTX).
The letter described a proposal to acquire all of the company's common stock for $1.60 per
share which represents an 80% premium on the average price of $0.88 over the past 10 days, in which one share of NLTX will be exchanged for $1.00 in cash plus $0.60, or 0.05 share of Biomed Industries. As NLTX has 42,818,346 outstanding shares, Biomed’s proposed offer has an enterprise value at $68.5 million.
Please visit the link of press release from AccessWire:
Biomed Industries, Inc. offers to acquire Neoleukin Therapeutics
About Biomed Industries, Inc.
Biomed Industries™, Inc. is a bio-pharmaceutical company committed to the development and commercialization of new drug therapeutics for unmet needs. Biomed is a leading innovator, having discovered a new family of clinical stage drugs for the treatment of Alzheimer’s disease. The Company is also developing new applications of AI for drug discovery, clinical trials recruitment and execution, and other mission critical areas in the pharmaceutical and medical device industry. For more information, please visit https://www.biomedind.com
-
CONTACT:
Biomed Industries, Inc.
San Jose, CA 95131 USA
Tel. 800-824-5135
Michael Willis
Email: media@biomedind.com
___________________________________________________________________________________________________________
San Jose, CA – August 15, 2023 (PRESS RELEASE)
Biomed Industries, Inc. ™ Inc. (Headquarters: San Jose, California, USA, CEO: Lloyd L. Tran, “Biomed”)
Biomed Industries, Inc. (Biomed) announced results today from its Phase 1B clinical trial of NA-831 for the treatment of Major Depression Disorder (MDD). The Phase 1B pilot study was a randomized, double-blind, fixed-dose, placebo-controlled, active reference study to investigate the efficacy, safety, and tolerability of two fixed doses (20 and 40 mg/d) of NA-831 vs. placebo after 6-week treatment in 32 adult patients with major depressive disorder (MDD). Venlafaxine XR was used as the active reference.
The difference between active treatment and placebo of ∼7 points on the MADRS translates into a clinically relevant difference in response rates of 32.5 % units, compared to an average of 16% units for antidepressants approved by the FDA and European health authorities. Treatment with NA-831 for 6 weeks was well tolerated and efficacious in reducing depressive and anxious symptoms in patients with MDD, and with fewer adverse events than drugs currently on the market.
According to the WHO, major depressive disorder is one of the leading causes of disability. Approximately 21 million adults in the US and 350 million people worldwide suffer from this mental disorder. Even though there are drugs developed for the management of depression, one of the challenges in dealing with this disease is that a significant portion of the patients develop treatment-resistant depression in which the patients fail to respond to drugs or other therapeutic approaches.
"NA-831 can serve as a potential anti-depressive agent by increasing the extracellular levels of serotonin (5-HT), noradrenaline, dopamine, acetylcholine and histamine in the prefrontal cortex and hippocampus." Said Lloyd L. Tran, CEO of Biomed Industries, Inc. He continued: "Our previous trials of NA-831 showed proof of safety and efficacy for the treatment of Alzheimer's disease. Those studies and this one also link the correlation between major depressive disorder and Alzheimer's disease. We are excited about the results of this Phase 1B study and are designing a protocol for a Phase 3 study treating MDD".
About Biomed Industries, Inc.
Biomed Industries™, Inc. is a bio-pharmaceutical company committed to the development and commercialization of new drug therapeutics for unmet needs. Biomed is a leading innovator, having discovered a new family of clinical stage drugs for the treatment of Alzheimer's disease and other neurological disorders. The Company is also developing new applications of AI for drug discovery, clinical trials recruitment and execution, and other mission critical areas in the pharmaceutical and medical device industry. For more information, please visit https://www.biomedind.com
CONTACT
Michael Willis
Biomed Industries, Inc.
San Jose, CA 95131 USA
Tel. 800-824-5135
Email: media@biomedind.com
____________________________________________________________________________________________________________
San Jose, CA – June 17, 2023 (PRESS RELEASE)
Biomed Industries, Inc. ™ Inc. (Headquarters: San Jose, California, USA, CEO: Lloyd L. Tran, “Biomed”)
Biomed Industries, Inc. (Biomed) introduced the Neurogenesis Hypothesis for Alzheimer's Disease and presented results of its Phase 2A clinical trial of NA-831 for the treatment of Alzheimer’s Disease (AD) at the International Conference on Neurology and Neurological Disorders, on June 16-17, 2023 in Rome, Italy ("Neurology 2023").
The absence of disease-modifying drug treatments for Alzheimer’s Disease (AD) today can be attributed to the yet unproven Amyloid Cascade Hypothesis, which has dominated drug discovery and clinical development in AD for 30 years. Almost all Alzheimer drug candidates based on the Amyloid Hypothesis have failed.
At the Neurology 2023, Biomed introduced the Neurogenesis Hypothesis as a potential replacement of the Amyloid Hypothesis. The Company also presented the Phase 2A clinical data of its new drug, NA-831, which can be taken orally for the treatment of Alzheimer’s Disease. NA-831 is based on the guidance of the Neurogenesis Hypothesis.
The hippocampus, a brain area critical for learning and memory, contains neural progenitor cells (NPCs) that continue to generate new neurons throughout life, a process known as adult hippocampal neurogenesis (AHN). Hippocampal neurogenesis is persistent through the tenth decade of human life and is detectable in patients with Alzheimer’s disease (AD).
There is a marked and progressive decline of DCX+ cell numbers in AD patients as compared with neurologically healthy individuals. AHN impairment compromises hippocampal function in Alzheimer's disease and Mild Cognitive Impairment.
It was further discovered that AHN impairment appears to take place prior to the presence of amyloid plaques and neurofibrillary tangles (NFTs), both of which are key pathological hallmarks of AD, in the dentate gyrus.
Most currently approved AD drugs target these plaques and, unfortunately, have not shown clinical benefit in treating the disease as yet. As a consequence, they have not been approved for reimbursement by the Center for Medicaid and Medicare Services (Medicare).
In a recent article entitled "The Amyloid Cascade Hypothesis in Alzheimer’s Disease: Should We Change Our Thinking?", published in the journal Biomolecules, Kurkinen and colleagues concluded that for Eisai’s lecanemab, the “claimed figure of 27% slowed cognitive decline was misleading. The actual figure was only 9.3% and it was unlikely to provide clinically meaningful benefit in people living with mild to moderate Alzheimer’s disease.”
NA-831 was found to easily cross the Blood-brain barrier and serve as a catalyst to restore neurogenesis and generate new neurons in the hippocampus in Alzheimer’s patients, leading to improved cognitive function.
With the completion of the Phase 2A clinical trial, which showed a significant improvement for patients with MCI, and mild to moderate Alzheimer’s disease as measured by ADAS Cog 13 after 24 weeks, Biomed is launching Phase 3 trials in the USA and a number of countries around the world.
“With the long history of drugs targeting Amyloid Beta in the treatment of AD showing no real clinical benefit, the time to more broadly explore and rapidly expand the Neurogenesis hypotheses has come”, said Lloyd L. Tran, Chairman and CEO of Biomed. He continued: ”We believe that our Neurogenesis drug, NA-831, acting alone or in conjunction with drugs from Biogen, Eisai, Eli Lily, and others, is an exciting new pathway for the treatment of Alzheimer’s Disease. Working with the JP Morgan M&A team enables us to form strategic partnerships with major pharmaceutical companies to bring NA-831 to the global market.”
About Biomed Industries, Inc.
Biomed Industries™, Inc. is a bio-pharmaceutical company committed to the development and commercialization of new drug therapeutics for unmet needs. Biomed is a leading innovator, having discovered a new family of clinical stage drugs for the treatment of Alzheimer’s disease. The Company is also developing new applications of AI for drug discovery, clinical trials recruitment and execution, and other mission critical areas in the pharmaceutical and medical device industry. For more information, please visit https://www.biomedind.com
-
CONTACT:
Biomed Industries, Inc.
San Jose, CA 95131 USA
Tel. 800-824-5135
Michael Willis
Email: media@biomedind.com
-------------------------------------------------------------------------------------------------------------
San Jose, CA – April 2, 2023 (PRESS RELEASE)
Biomed Industries, Inc. ™ Inc. (Headquarters: San Jose, California, USA, CEO: Lloyd L. Tran, “Biomed”)
Biomed Industries, Inc. (Biomed) introduced a new approach and presented results of its Phase 2A clinical trial of NA-831 for the treatment of Alzheimer’s Disease (AD) at the Alzheimer's Disease/Parkinson's Disease International Conference, March 28-April 2, 2023 in Gothenburg, Sweden.
The absence of disease-modifying drug treatments for Alzheimer’s Disease (AD) today can be attributed to the yet unproven Amyloid Cascade Hypothesis, which has dominated drug discovery and clinical development in AD for 30 years. Almost all Alzheimer drug candidates based on the Amyloid Hypothesis have failed.
At the AD/PD 2023, Biomed introduced the Neurogenesis Hypothesis as a potential replacement of the Amyloid Hypothesis. The Company also presented the Phase 2A clinical data of its new drug, NA-831, which can be taken orally for the treatment of Alzheimer’s Disease. NA-831 is based on the guidance of the Neurogenesis Hypothesis.
The hippocampus, a brain area critical for learning and memory, contains neural progenitor cells (NPCs) that continue to generate new neurons throughout life, a process known as adult hippocampal neurogenesis (AHN). Hippocampal neurogenesis is persistent through the tenth decade of human life and is detectable in patients with Alzheimer’s disease (AD).
AHN impairment compromises hippocampal function and appears to take place prior to the presence of senile plaques and neurofibrillary tangles (NFTs), both of which are key pathological hallmarks of AD. Most currently approved AD drugs target these plaques and, unfortunately, have not shown clinical benefit in treating the disease as yet. As a consequence, they have not been approved for reimbursement by the Center for Medicaid and Medicare Services (Medicare).
In a recent article entitled "The Amyloid Cascade Hypothesis in Alzheimer’s Disease: Should We Change Our Thinking?", published in the journal Biomolecules, Kurkinen and colleagues concluded that for Eisai’s lecanemab, the “claimed figure of 27% slowed cognitive decline was misleading. The actual figure was only 9.3% and it was unlikely to provide clinically meaningful benefit in people living with mild to moderate Alzheimer’s disease.”
NA-831 was found to easily cross the Blood-brain barrier and serve as a catalyst to restore neurogenesis and generate new neurons in the hippocampus in Alzheimer’s patients, leading to improved cognitive function.
With the completion of the Phase 2A clinical trial, which showed a significant improvement for patients with MCI, and mild to moderate Alzheimer’s disease as measured by ADAS Cog 13 after 24 weeks, Biomed is launching Phase 3 trials in the USA and a number of countries around the world.
“With the long history of drugs targeting Amyloid Beta in the treatment of AD showing no real clinical benefit, the time to more broadly explore and rapidly expand the Neurogenesis hypotheses has come”, said Lloyd L. Tran, Chairman and CEO of Biomed. He continued: ”We believe that our Neurogenesis drug, NA-831, acting alone or in conjunction with drugs from Biogen, Eisai, Eli Lily, and others, is an exciting new pathway for the treatment of Alzheimer’s Disease. Working with the JP Morgan M&A team enables us to form strategic partnerships with major pharmaceutical companies to bring NA-831 to the global market.”
About Biomed Industries, Inc.
Biomed Industries™, Inc. is a bio-pharmaceutical company committed to the development and commercialization of new drug therapeutics for unmet needs. Biomed is a leading innovator, having discovered a new family of clinical stage drugs for the treatment of Alzheimer’s disease. The Company is also developing new applications of AI for drug discovery, clinical trials recruitment and execution, and other mission critical areas in the pharmaceutical and medical device industry. For more information, please visit https://www.biomedind.com
____________________________________________________________________________________________________
SAN JOSE, CA, September 19, 2022/- Biomed Industries, Inc. (“BIOMED” or the “Company”), announced that it has entered into a definitive share exchange agreement with MedAware Systems, Inc. (“MedAware”) for the acquisition of all of the issued and outstanding shares of MedAware (the “Transaction”).
View the announcement on PR.com:
https://pdf.pr.com/press-release/pr-869798.pdf
The Boards of Directors of BIOMED and MedAware have each approved the Share Exchange, pursuant to which all of the rights, titles and interests of all issued and outstanding of common shares of capital stock of MedAware will be exchanged for common stock of BIOMED at a ratio of 5.34 shares of MedAware for 1 new common share of BIOMED.
It was agreed that the market value of MedAware shares was $1.50 per share and the market value of BIOMED’s share was $8.00 per share, with the transaction valued at an aggregate of $18 million, to be paid in the form of 2,259,170 common shares of BIOMED. On the date of the Agreement, BIOMED has approximately 76,354,075 common shares and no preferred share outstanding.
Upon completion of the Transaction, Dr. Zung Vu Tran, the Co-founder and Chairman of MedAware will be appointed to the Board of Directors of BIOMED. Mr. Michael Willis, the CEO of MedAware will continue to serve as the President of MedAware, a wholly owned subsidiary of BIOMED.
“Biomed Industries, Inc. welcomes the management team and shareholders MedAware Systems, Inc. to be a part of Biomed. MedAware has cultivated outstanding talent. We plan to collaborate with MedAware to further develop its bio-informatics and machine learning technology to optimize and expand Biomed’s drug development in finding treatment and prevention for neurodegenerative diseases. BIOMED is at an inflection point for accelerating growth and value creation” said Lloyd L. Tran, the Chairman and CEO of BIOMED.
“We are excited to be joining with Biomed Industries as they pioneer novel therapies for Alzheimer’s disease and other neurodegenerative disorders”, said Michael Willis, CEO. He continued: “Our massive data set on dementia, culled from over 3,000 clinical trials as well as over 7,000 published papers on the topic will empower deep analysis of the state-of-the-art in the field and to focus our considerable AI and machine learning capabilities to rapidly accelerate new drug development. We will also expand our current work with pharmaceutical and medical device companies under the aegis of a much larger organization to accelerate market penetration and revenue growth.”
The Board of Directors of MedAware having approved this Agreement, have scheduled a shareholder meeting to vote on the Share Exchange Agreement and Plan of Reorganization on or before September 28, 2022.
Approval for the Transaction will be sought from BIOMED’s shareholders at a special meeting of shareholders currently scheduled for September 30, 2022, which will be held electronically.
About Biomed Industries, Inc.
Biomed Industries™, Inc. is a bio-pharmaceutical company committed to the development and commercialization of new drug therapeutics for unmet needs. Biomed is a leading innovator, having discovered a new family of drugs which are in the clinical stage for the treatment of Alzheimer’s disease. Biomed is the first to develop a new hypothesis known as the Neurogenesis Hypothesis to replace the amyloid hypothesis as the new approach to treat Alzheimer’s disease.
For more information, please visit the website: https://www.biomedind.com
MedAware Systems, Inc.
MedAware Systems is a growth stage, next generation medical data and analytics company. Combining Real World Evidence (RWE) extracted from government adverse event databases and social media with scientific data from published medical research (meta-analysis), the Company provides unprecedented business intelligence to support regulatory filings, competitive analysis, and marketing messaging.
For more information, please visit the website: https://medawaresystems.com
For further information, please contact:
Biomed Industries, Inc.
San Jose, CA 95131 USA
Tel. 800-824-5135
Email: media@biomedind.com
www.biomedind.com
San Jose, CA – December 2, 2022 (PRESS RELEASE)
Biomed Industries, Inc. ™ Inc. (Headquarters: San Jose, California, USA, CEO: Lloyd L. Tran, “Biomed”) presented Phase 2A clinical results of NA-831, and the proposed Phase 3 clinical proptol of NA-831 at the Clinical Trials of Alzheimer's Disease (CTAD) International Conference,
November 31 to Devember 2, 2022, San Francisco, California, United States.
Title: “Proposing the neurogenesis hypothesis for Alzheimer’s disease with a case study- phase 2 clinical trials of NA-831”
Authors: Lloyd Tran, and Markku Kurkinen
Title: “A Phase 3 Clinical Trial Protocol to Evaluate the Efficacy and Safety of NA-831 in Subjects with Early Onset of Alzheimer's Disease”
Authors: Lloyd Tran, Fern Vu and Markku Kurkinen
At the AAIC 2022, Lloyd Tran, the Chairman and CSO of Biomed presented the Neurogenesis Hypothesis for Alzheimer’s (NHA) and the results of the clinical trial Phase 2A of NA-831 that supports the hypothesis. This was the first time that the Neurogenesis Hypothesis for Alzheimer has been presented with supported clinical data at the CTAD International Conference.
The hypothesis can be summarized as below:
* The hippocampus is critical for learning and memory.
* The hippocampus continues to generate new neurons throughout life, a process is known as adult hippocampal neurogenesis (AHN).
* There was a marked and progressive decline of DCX+ cell numbers in AD patients as compared with neurologically healthy individuals.
* AHN impairment compromises hippocampal function in AD and MCI.
* This indicates that reduced AHN causes memory impairments and cognitive deterioration in the disease.
* Therefore, stimulating inherent AHN could serve as a therapeutic target for improving cognitive function and promoting synaptic resilience.
Alzheimer’s Disease is a progressive and irreversible neurodegenerative disorder that affects millions of people worldwide. Today, more than 5.8 million people in the United States and 45 million people worldwide live with Alzheimer’s. There is currently no cure, no prevention and no treatment of Alzheimer’s disease.
The study was a randomized, double-blind, placebo-controlled parallel-group Phase 2A clinical study of NA-831, conducted in patients with mild cognitive impairment (MCI), and patients with mild and moderate Alzheimer’s disease over 24 weeks, with a follow-up for an additional 24 weeks. In addition to the primary safety objective, the study assessed the efficacy in terms of clinical symptoms, which were exploratory objectives in this study.
In an early stage of Alzheimer's disease (“mild Alzheimer’s) a person may function independently and can still drive, work and be part of social activities. Moderate Alzheimer's is typically the longest stage and can last for many years. During the moderate stage of Alzheimer’s, the dementia symptoms are more pronounced. As the disease progresses, the person with Alzheimer's will require a greater level of care.
NA-831™is a small drug molecule that exhibits neuroprotection, i.e. can prevent or slow disease progression by halting or at least slowing the loss of neurons. The drug also exhibits neurogenesis, and cognitive protective properties across a range of disease models. Neurogenesis is the process by which new neurons are generated from neural stem cells in the adult. Neurogenesis is reported to play a role in learning, memory and cognitive functions.
NA-831™ has been shown to be safe and well tolerated in healthy volunteers.
The results suggest that NA-831 could slow decline in cognitive function of patients with MCI due to Alzheimer’s disease, or mild to moderate dementia due to Alzheimer’s disease.
NA-831 was well-tolerated at 30 mg per day administered orally. There were no serious adverse events.
This press release discusses investigational uses of agents in development.
About Biomed Industries, Inc.
Biomed Industries™, Inc. is a bio-pharmaceutical company committed to the development and commercialization of new drug therapeutics for unmet needs. Biomed is a leading innovator, having discovered a new family of clinical stage drugs for the treatment of Alzheimer’s disease. The Company is also developing new applications of AI for drug discovery, clinical trials recruitment and execution, and other mission critical areas in the pharmaceutical and medical device industry. For more information, please visit https://www.biomedind.com
-
CONTACT:
Biomed Industries, Inc.
San Jose, CA 95131 USA
Tel. 800-824-5135
Michael Willis
Email: media@biomedind.com
---------------------------------------------------------------------------------------------------------
San Jose, CA – August 4, 2022 (PRESS RELEASE)
Biomed Industries, Inc. ™ Inc. (Headquarters: San Jose, California, USA, CEO: Lloyd L. Tran, “Biomed”) presented 3 poster presentations on NA-831 at the Alzheimer's Association International Conference, July 31- August 4, 2022 in San Diego, California, United States.
Title: “Proposing the neurogenesis hypothesis for Alzheimer’s disease with a case study- phase 2 clinical trials of NA-831”
Authors: Lloyd Tran, and Markku Kurkinen
Title: “Alzheimer drug candidate NA-831 for the treatment of Dementia caused by Covid-19- A Phase 2/3 clinical trial methodology”
Authors: Lloyd Tran, and Markku Kurkinen
Title: “A Phase 3 Clinical Trial Protocol to Evaluate the Efficacy and Safety of NA-831 in Subjects with Early Onset of Alzheimer's Disease”
Authors: Lloyd Tran, Fern Vu and Markku Kurkinen
At the AAIC 2022, Lloyd Tran, the Chairman and CSO of Biomed presented the Neurogenesis Hypothesis for Alzheimer’s (NHA) and the results of the clinical trial Phase 2A of NA-831 that supports the hypothesis. This was the first time that the Neurogenesis Hypothesis for Alzheimer has been presented with supported clinical data. The hypothesis can be summarized as below:
* The hippocampus is critical for learning and memory.
* The hippocampus continues to generate new neurons throughout life, a process is known as adult hippocampal neurogenesis (AHN).
* There was a marked and progressive decline of DCX+ cell numbers in AD patients as compared with neurologically healthy individuals.
* AHN impairment compromises hippocampal function in AD and MCI.
* This indicates that reduced AHN causes memory impairments and cognitive deterioration in the disease.
* Therefore, stimulating inherent AHN could serve as a therapeutic target for improving cognitive function and promoting synaptic resilience.
Alzheimer’s Disease is a progressive and irreversible neurodegenerative disorder that affects millions of people worldwide. Today, more than 5.8 million people in the United States and 45 million people worldwide live with Alzheimer’s. There is currently no cure, no prevention and no treatment of Alzheimer’s disease.
The study was a randomized, double-blind, placebo-controlled parallel-group Phase 2A clinical study of NA-831, conducted in patients with mild cognitive impairment (MCI), and patients with mild and moderate Alzheimer’s disease over 24 weeks, with a follow-up for an additional 24 weeks. In addition to the primary safety objective, the study assessed the efficacy in terms of clinical symptoms, which were exploratory objectives in this study.
In an early stage of Alzheimer's disease (“mild Alzheimer’s) a person may function independently and can still drive, work and be part of social activities. Moderate Alzheimer's is typically the longest stage and can last for many years. During the moderate stage of Alzheimer’s, the dementia symptoms are more pronounced. As the disease progresses, the person with Alzheimer's will require a greater level of care.
NA-831™is a small drug molecule that exhibits neuroprotection, i.e. can prevent or slow disease progression by halting or at least slowing the loss of neurons. The drug also exhibits neurogenesis, and cognitive protective properties across a range of disease models. Neurogenesis is the process by which new neurons are generated from neural stem cells in the adult. Neurogenesis is reported to play a role in learning, memory and cognitive functions.
NA-831™ has been shown to be safe and well tolerated in healthy volunteers.
The results suggest that NA-831 could slow decline in cognitive function of patients with MCI due to Alzheimer’s disease, or mild to moderate dementia due to Alzheimer’s disease.
NA-831 was well-tolerated at 30 mg per day administered orally. There were no serious adverse events.
This press release discusses investigational uses of agents in development.
MEDIA CONTACTS
Biomed Industries, Inc.
San Jose, CA 95131 USA
Tel. 1-800-824-5135
media@biomedind.com
http://www.biomedind.com
For further information about our products, please contact us.